DRS

New Peer-Reviewed Study Finds That Masimo SET® Pulse Oximetry Measures Accurately on Both Black and White People Even During Low Perfusion

Retrieved on: 
Thursday, February 8, 2024
General Health, Health, Medical Devices, Hospitals, Health Technology, Wearables, Mobile Technology, Technology, Clinical Trials, Black and White, Carboxyhemoglobin, Perfusion, Bias, FDA, White, Skin, Pulse, Oxygen saturation, Multimedia, RD, Methemoglobin, Journal, Pigment, MASI, Oxygen saturation (medicine), DRS, Data, ARMS, Medical device

Barker and Wilson analyzed Masimo laboratory data obtained from self-identified Black and White volunteer subjects to evaluate differences in Masimo pulse oximetry accuracy and bias on the basis of skin tone.

Key Points: 
  • Barker and Wilson analyzed Masimo laboratory data obtained from self-identified Black and White volunteer subjects to evaluate differences in Masimo pulse oximetry accuracy and bias on the basis of skin tone.
  • To that end, they abstracted Pi values from their dataset, and divided them into “low perfusion” (Pi ≤ 1) and “normal perfusion” (Pi > 1) groups.
  • For the subset of Black subjects, there was bias and precision of -0.26% ± 1.37%, and for White subjects, -0.12% ± 1.31%.
  • In the low perfusion group, there was overall bias and precision of 0.48% ± 1.59%, with accuracy of 1.64% ARMS.

Caron Treatment Centers Expands Its Neurorestorative Health Care Services

Retrieved on: 
Thursday, February 8, 2024
Health, General Health, Assessment, Personality, Hope, Insurance, Brain, Substance abuse, Depression, FDG-PET, Brain mapping, Dementia, Psychology, Ocean Drive, Anxiety, Function (mathematics), Addiction medicine, MRO, Neuro, Attention, Family, Neuroimaging, Mental health, Deficit spending, Chronic pain, Trauma, Mental, QEEG, Patient, Myenteric plexus, DRS, Medicine, Research, Memory, Life, Doctor of Philosophy, Hospital, Biomarker

Caron Treatment Centers , a nonprofit behavioral healthcare leader for almost 70 years dedicated to treatment, research, prevention and addiction medical education, announces the expansion of its groundbreaking Neurorestorative Health Care services provided at The Keele Medical Center in Delray Beach, Fl.

Key Points: 
  • Caron Treatment Centers , a nonprofit behavioral healthcare leader for almost 70 years dedicated to treatment, research, prevention and addiction medical education, announces the expansion of its groundbreaking Neurorestorative Health Care services provided at The Keele Medical Center in Delray Beach, Fl.
  • “We’re excited to share this expertise more broadly and expand our Neurorestorative Health Care offerings to help more individuals optimize their brain health.”
    Individuals interested in more information about Caron’s 10-day Neurocognitive Assessment or its Neurorestorative Health Care can visit caron.org/neuro-assessment or call 877-369-0109.
  • Caron Treatment Centers is an internationally recognized nonprofit dedicated to addiction and behavioral healthcare treatment, research, prevention, and addiction medicine education.
  • Caron also provides concierge signature treatment for executives, healthcare professionals and older adults and offers Neurorestorative Health Care at our Keele Medical Center in Palm Beach County, Fl.

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Retrieved on: 
Thursday, February 8, 2024
IBD, Trial of the century, Division, Inflammatory bowel disease, Therapy, CAB, Nutrition, DRS, Mount Sinai Health System, Ulcerative colitis, Associate, Pharmaceutical industry

Drs.

Key Points: 
  • Drs.
  • Sands and Rieder will be advising Palisade on the advancement of its product candidates from preclinical studies to clinical trials.
  • “We are committed to advancing the treatment landscape for Inflammatory Bowel Disease (IBD) and believe that the appointment of these preeminent key opinion leaders will assist in the development of a precision approach for IBD treatment,” commented J.D.
  • Finley, Chief Executive Officer of Palisade.

TeleSpecialists Celebrates a Decade of Excellence in Telemedicine

Retrieved on: 
Wednesday, February 7, 2024
Partnership, COVID-19, Telehealth, Continuing medical education, DPM, Research, MD, MBA, Physician, DRS, Telepsychiatry, Education, Conference, Hospital

FORT MYERS, Fla., Feb. 7, 2024 /PRNewswire/ -- TeleSpecialists, LLC, a telemedicine industry leader and physician-owned company, marks a decade of transformative healthcare with a journey that began in 2013. Founded by a group of visionary physicians, the company took its first patient in 2014, embarking on a mission to redefine telehealth.

Key Points: 
  • FORT MYERS, Fla., Feb. 7, 2024 /PRNewswire/ -- TeleSpecialists, LLC, a telemedicine industry leader and physician-owned company, marks a decade of transformative healthcare with a journey that began in 2013.
  • TeleSpecialists expanded its services in 2021 by introducing TelePsychiatry, further solidifying its commitment to comprehensive telehealth solutions and reaffirming its role in healthcare.
  • Daryoush Zafar, DPM, MBA, one of TeleSpecialists' founding partners, shared his sentiments, "It's been an incredible ride over the last decade.
  • TeleSpecialists remains dedicated to its mission of providing exceptional telemedicine services and shaping the future of healthcare.

Akerna Corp. Announces Anticipated Closing of the Merger with Gryphon Digital Mining, Inc. and Reverse Stock Split

Retrieved on: 
Wednesday, February 7, 2024
Transfer, CUSIP, Mergers and acquisitions, Book, DRS, Sale, Security (finance)

Prior to closing the Merger, Akerna anticipates completing a reverse stock split of its common stock at a ratio of one share for twenty shares.

Key Points: 
  • Prior to closing the Merger, Akerna anticipates completing a reverse stock split of its common stock at a ratio of one share for twenty shares.
  • The estimated exchange ratio of shares of Akerna’s common stock for Gryphon common stock and Gryphon preferred stock will be approximately 1.5561 shares of Akerna common stock for each one share of Gryphon Common Stock and Preferred Stock based on estimated aggregate merger consideration of 31,539,011 shares of Akerna common stock, on a post-reverse stock split basis.
  • The reverse stock split is in relation to the anticipated closing of the Merger and is contingent upon the Merger closing.
  • The reverse stock split did not alter the par value of Akerna common stock or modify any voting rights or other terms of our shares of Akerna common stock.

HILL'S PET NUTRITION PARTNERS WITH "CRITTER FIXERS" VETERINARIANS TO HELP END PET OBESITY, A TOP HEALTH THREAT

Retrieved on: 
Wednesday, February 7, 2024
Parent, Overweight, Obesity, Nat Geo Wild, L.O.V.E, Overalls, Dog, Hill, Risk, DRS, Metabolism, Cat, Health, Pet, Shenoy, Pet industry

OVERLAND PARK, Kan., Feb. 7, 2024 /PRNewswire/ -- Obesity is one of the top health threats pets face, with 59% of dogs and 61% of cats in the U.S. classified as overweight or obese in 2022, according to the Association for Pet Obesity Prevention. Hill's Pet Nutrition is teaming up with Drs. Vernard Hodges and Terrence Ferguson, stars of Nat Geo Wild's "Critter Fixers: Country Vets," to raise awareness of the pet obesity issue and share easy ways pet parents can help their dogs and cats lose weight and be healthier.

Key Points: 
  • "One in three pet parents don't recognize their pet's weight issue.1 By joining the Hill's Pet Nutrition End Pet Obesity campaign, we aim to spread the word about the importance of ending pet obesity."
  • Even if pet parents think their pets are at the right weight, it's important to watch out for changes.
  • "We encourage pet parents to take a proactive approach to maintaining their pet's weight," Ferguson said.
  • More than 70% of pets lost weight within 10 weeks when fed Hill's Science Diet Perfect Weight nutrition.

Advances Made in Grant to Improve Immunotherapy in Gastroesophageal Cancer

Retrieved on: 
Wednesday, February 7, 2024
Antigen, Massachusetts General Hospital, Immunotherapy, Research, GEA, Stomach cancer, Patient, Safety, Bone marrow, Dana–Farber Cancer Institute, DRS, Cancer, Doctor of Philosophy, De Gregorio, GEMINI, Pharmaceutical industry

They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.

Key Points: 
  • They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.
  • One immunotherapy that has shown very positive results in blood cancers is Chimeric Antigen Receptor (CAR) T cell therapy.
  • "We are indeed proud to play a part in the development of the next-generation cellular therapy for gastroesophageal cancer by Drs.
  • Dana-Farber Cancer Institute provides expert cancer care while advancing the understanding of cancer and related diseases.

For Women, By Women: The Violet Group Announces Launch Of Online Learning And Development Community, The Violet Collective

Retrieved on: 
Wednesday, February 7, 2024
Learning, The Dandy, Workplace, Doctor of Philosophy, The Essentials, Woman, DRS, Management

CHICAGO, Feb. 7, 2024 /PRNewswire/ -- The Violet Group is excited to announce the opening of The Violet Collective, a dynamic community founded by two accomplished PhD-level Organizational Psychologists and Executive Coaches, Stefanie Mockler and Kelly Levin. The founders created the community to tangibly improve women's access to high quality learning and development experiences, and ultimately elevate more women into decision-making and leadership roles.

Key Points: 
  • CHICAGO, Feb. 7, 2024 /PRNewswire/ -- The Violet Group is excited to announce the opening of The Violet Collective, a dynamic community founded by two accomplished PhD-level Organizational Psychologists and Executive Coaches, Stefanie Mockler and Kelly Levin.
  • The founders created the community to tangibly improve women's access to high quality learning and development experiences, and ultimately elevate more women into decision-making and leadership roles.
  • The Violet Collective aims to revolutionize access to high impact leadership and professional development for women.
  • Membership into "The Essentials" within The Violet Collective includes access to:
    "Office Hours" Group Coaching with our co-founders, Drs.

NCLA Asks Supreme Court to Uphold Injunction Against Government Social Media Censorship

Retrieved on: 
Tuesday, February 6, 2024
Security (finance), Plaintiff, Supreme court, COVID-19 vaccine, Government, FBI, Attorney, COVID-19, The Daily Wire, Safety, Supreme, Constitutional right, First, Marketing, Father, CDC, Speech, Social media, CISA, Fifth, White, NCLA, The Administrative State, DRS, Judge, Federalist

The injunction would bar officials from the White House, CDC, FBI, Cybersecurity and Infrastructure Security Agency (CISA), and Surgeon General’s office from coercing or significantly encouraging social media platforms to censor constitutionally protected speech.

Key Points: 
  • The injunction would bar officials from the White House, CDC, FBI, Cybersecurity and Infrastructure Security Agency (CISA), and Surgeon General’s office from coercing or significantly encouraging social media platforms to censor constitutionally protected speech.
  • In September, a Fifth Circuit panel upheld the key components of U.S. District Judge Terry Doughty’s July 4 preliminary injunction order, prohibiting named federal officials from coercing or significantly encouraging social media companies to suppress legal speech.
  • Though the U.S. Supreme Court has temporarily stayed the Fifth Circuit’s injunction, NCLA believes the Justices are ultimately unlikely to permit the egregious First Amendment abridgements this case has exposed.
  • In fact, much of the speech the government suppressed in this case—about Covid-19 and Hunter Biden’s laptop—was truthful.”
    — Mark Chenoweth, President and Chief Legal Officer, NCLA

Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements

Retrieved on: 
Tuesday, February 6, 2024
Skin cancer, COVID-19, Inflammation, Pneumonia, Immune system, SRT, Patient, BOCA, Dermatology, COVID, Rheumatoid arthritis, Radiation, Keloid, Poaceae, Physician, Malignancy, DRS, Radiation therapy, Education, Skin, Health, Medical imaging

BOCA RATON, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a new multi-faceted collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, Calif. 

Key Points: 
  • Under the collaboration, CureRays will provide Sensus’ dermatology customers with oversight and supervision to assure patient safety, quality, reliability of outcomes and conformance with regulatory requirements, in particular in states where regulations covering the use of ionizing radiation have been tightened.
  • In addition, CureRays will research new indications for Sensus’ superficial radiotherapy (SRT and IG-SRT), including inflammatory diseases.
  • We were anxious to help stem fatalities in any way we could, and we’ve been impressed with their commitment to patient care.
  • My goal is also to help further enhance patient selection against the risks and benefits of radiotherapy.”